Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Naoya Yamazaki et al.|OncoImmunology|2016Cited by 178
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapyDaisuke Nobuoka, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|Cancer Immunology Immunotherapy|2012Cited by 48
Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccinationYu Sawada, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|Human Vaccines & Immunotherapeutics|2013Cited by 30
Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinomaKazuya Ofuji, Tetsuya Nakatsura, Keigo Saito et al.|Oncotarget|2016Cited by 28
Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytesYu Akazawa, Tetsuya Nakatsura, Daisuke Nobuoka et al.|Cancer Science|2019Cited by 16